Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
pharmafile | June 7, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinistÂ
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of lung cancer showed an overall response rate in 36 of 57 patients.
The data included study for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results from Phase II study of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) in patients with BRAF V600E-mutation positive NSCLC.
Thirty-six of 57 patients showed a clinical response; of these patients, 50% (18 of 36) continued to respond to treatment at the time of analysis, the company said in a statement.
One-to-two percent (1-2%) of patients with NSCLC have a BRAF V600E mutation, which is associated with more aggressive tumors and a poorer prognosis, independent of smoking status.
Alessandro Riva, global head of Novartis Oncology Development and Medical Affairs, said: “Lung cancer is the number one cause of cancer death world-wide, and more than half of NSCLC patients’ tumors occur as a result of a genetic mutation. Novartis is fully committed to bringing forth new, targeted options for NSCLC patients, many of whom remain underserved by today’s available therapies.”
David Planchard, trial’s principal investigator, said: “This study confirms a fourth actionable biomarker in NSCLC – BRAFV600E – after EGFR, ALK and ROS-1. The potential to treat this oncogene gives hope to a very small, underserved patient population.”
Overall survival rate is the percentage of patients whose cancer shrinks or disappears after treatment. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works.
Combination use of Tafinlar and Mekinist in patients with unresectable or metastatic melanoma who have a BRAF V600 mutation is approved in the US, EU, Australia, Canada and additional countries.
Anjali Shukla
Related Content
Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …
SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …
Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …
